The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells

Science Signaling

Volumn 6, Issue 287, 2013, Pages

  Meyer, Aaron S ^a,b   Miller, Miles A ^a   Gertler, Frank B ^b   Lauffenburger, Douglas A ^a,b  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AEW 541; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; INSULIN RECEPTOR; LAPATINIB; NVP AEW 541; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN AXL; PROTEIN TYROSINE KINASE; R 428; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; AXL RECEPTOR TYROSINE KINASE; EGFR PROTEIN, HUMAN; INSR PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; MET PROTEIN, HUMAN; ONCOPROTEIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR;

ARTICLE; AXL GENE; CANCER CELL; CANCER RESISTANCE; CELL MOTILITY; CLASSIFICATION; CONTROLLED STUDY; CROSS LINKING; DATA BASE; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; GENE; GENE INTERACTION; GENE SILENCING; IMMUNOPRECIPITATION; MACHINE LEARNING; MARKER GENE; PREDICTIVE VALUE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; BIOSYNTHESIS; BREAST TUMOR; CELL MOTION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ANTIGENS, CD; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION;

EID: 84884167635     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2004155     Document Type: Article

References (62)

1. Y. Yarden, G. Pines, The ERBB network: At last, cancer therapy meets systems biology. Nat. Rev. Cancer 12, 553-563 (2012).
2. N. Hynes, H. Lane, ERBB receptors and cancer: The complexity of targeted inhibitors. Nat. Rev. Cancer 5, 341-354 (2005).
3. T. R. Wilson, J. Fridlyand, Y. Yan, E. Penuel, L. Burton, E. Chan, J. Peng, E. Lin, Y. Wang, J. Sosman, A. Ribas, J. Li, J. Moffat, D. P. Sutherlin, H. Koeppen, M. Merchant, R. Neve, J. Settleman, Widespread potential for growth-Factor-Driven resistance to anticancer kinase inhibitors. Nature 487, 505-509 (2012).
4. F. Harbinski, V. J. Craig, S. Sanghavi, D. Jeffery, L. Liu, K. A. Sheppard, S. Wagner, C. Stamm, A. Buness, C. Chatenay-Rivauday, Y. Yao, F. He, C. X. Lu, V. Guagnano, T. Metz, P. M. Finan, F. Hofmann, W. R. Sellers, J. A. Porter, V. E. Myer, D. Graus-Porta, C. J. Wilson, A. Buckler, R. Tiedt, Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth. Cancer Discov. 2, 948-959 (2012).
5. D. Ercan, K. Zejnullahu, K. Yonesaka, Y. Xiao, M. Capelletti, A. Rogers, E. Lifshits, A. Brown, C. Lee, J. G. Christensen, D. J. Kwiatkowski, J. A. Engelman, P. A. Janne, Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 29, 2346-2356 (2010).
6. I. F. Tannock, C. M. Lee, J. K. Tunggal, D. S. M. Cowan, M. J. Egorin, Limited penetration of anticancer drugs through tumor tissue: A potential cause of resistance of solid tumors to chemotherapy. Clin. Cancer Res. 8, 878-884 (2002).
7. J. Thiery, H. Acloque, R. Huang, M. Nieto, Epithelial-Mesenchymal transitions in development and disease. Cell 139, 871-890 (2009).
8. J. H. Taube, J. I. Herschkowitz, K. Komurov, A. Y. Zhou, S. Gupta, J. Yang, K. Hartwell, T. T. Onder, P. B. Gupta, K. W. Evans, B. G. Hollier, P. T. Ram, E. S. Lander, J. M. Rosen, R. A. Weinberg, S. A. Mani, Core epithelial-To-Mesenchymal transition interactome gene-Expression signature is associated with claudin-Low and metaplastic breast cancer subtypes. Proc. Natl. Acad. Sci. U.S.A. 107, 15449-15454 (2010).
9. B. A. Frederick, B. A. Helfrich, C. D. Coldren, D. Zheng, D. Chan, P. A. Bunn, D. Raben, Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-Small cell lung carcinoma. Mol. Cancer Ther. 6, 1683-1691 (2007).
10. L. A. Byers, L. Diao, J. Wang, P. Saintigny, L. Girard, M. Peyton, L. Shen, Y. H. Fan, U. Giri, P. Tumula, M. B. Nilsson, J. Gudikote, H. T. Tran, R. J. Cardnell, D. J. Bearss, S. L. Warner, J. M. Foulks, S. B. Kanner, V. Gandhi, N. L. Krett, S. T. Rosen, E. S. Kim, R. S. Herbst, G. R. Blumenschein, J. J. Lee, S. M. Lippman, K. K. Ang, G. B. Mills, W. K. Hong, J. N. Weinstein, I. I. Wistuba, K. Coombes, J. D. Minna, J. V. Heymach, An epithelial-Mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res. 19, 279-290 (2012).
11. S. Thomson, F. Petti, I. Sujka-Kwok, D. Epstein, J. D. Haley, Kinase switching in mesenchymal-Like non-Small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin. Exp. Metastasis 25, 843-854 (2008).
12. T. Arumugam, V. Ramachandran, K. F. Fournier, H.Wang, L. Marquis, J. L. Abbruzzese, G. E. Gallick, C. D. Logsdon, D. J. McConkey, W. Choi, Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 69, 5820-5828 (2009).
13. B. Aktas, M. Tewes, T. Fehm, S. Hauch, R. Kimmig, S. Kasimir-Bauer, Stem cell and epithelial-Mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 11, R46 (2009).
14. C. J. Creighton, X. Li, M. Landis, J. M. Dixon, V. M. Neumeister, A. Sjolund, D. L. Rimm, H. Wong, A. Rodriguez, J. I. Herschkowitz, C. Fan, X. Zhang, X. He, A. Pavlick, M. C. Gutierrez, L. Renshaw, A. A. Larionov, D. Faratian, S. G. Hilsenbeck, C. M. Perou, M. T. Lewis, J. M. Rosen, J. C. Chang, Residual breast cancers after conventional therapy display mesenchymal as well as tumor-Initiating features. Proc. Natl. Acad. Sci. U.S.A. 106, 13820-13825 (2009).
15. Q. Q. Li, J. D. Xu, W. J. Wang, X. X. Cao, Q. Chen, F. Tang, Z. Q. Chen, X. P. Liu, Z. D. Xu, Twist1-Mediated Adriamycin-Induced epithelial-Mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin. Cancer Res. 15, 2657-2665 (2009).
16. S. Thomson, F. Petti, I. Sujka-Kwok, P. Mercado, J. Bean, M. Monaghan, S. L. Seymour, G. M. Argast, D. M. Epstein, J. D. Haley, A systems view of epithelial-Mesenchymal transition signaling states. Clin. Exp. Metastasis 28, 137-155 (2011).
17. I. M. Shapiro, A. W. Cheng, N. C. Flytzanis, M. Balsamo, J. S. Condeelis, M. H. Oktay, C. B. Burge, F. B. Gertler, An EMT-Driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. PLoS Genet. 7, e1002218 (2011).
18. A. Lapuk, H. Marr, L. Jakkula, H. Pedro, S. Bhattacharya, E. Purdom, Z. Hu, K. Simpson, L. Pachter, S. Durinck, N. Wang, B. Parvin, G. Fontenay, T. Speed, J. Garbe, M. Stampfer, H. Bayandorian, S. Dorton, T. A. Clark, A. Schweitzer, A. Wyrobek, H. Feiler, P. Spellman, J. Conboy, J. W. Gray, Exon-Level microarray analyses identify alternative splicing programs in breast cancer. Mol. Cancer Res. 8, 961-974 (2010).
19. H. D. Kim, A. S.Meyer, J. P. Wagner,S.K.Alford, A. Wells, F. B. Gertler, D. A. Lauffenburger, Signaling network state predicts twist-Mediated effects on breast cell migration across diverse growth factor contexts. Mol. Cell. Proteomics 10, M111.008433 (2011).
20. R. J. Craven, L. H. Xu, T. M. Weiner, Y. W. Fridell, G. A. Dent, S. Srivastava, B. Varnum, E. T. Liu, W. G. Cance, Receptor tyrosine kinases expressed in metastatic colon cancer. Int. J. Cancer 60, 791-797 (1995).
21. T. Nemoto, K. Ohashi, T. Akashi, J. D. Johnson, K. Hirokawa, Overexpression of protein tyrosine kinases in human esophageal cancer. Pathobiology 65, 195-203 (1997).
22. M. Ito, M. Nakashima, T. Nakayama, A. Ohtsuru, Y. Nagayama, N. Takamura, E. P. Demedchik, I. Sekine, S. Yamashita, Expression of receptor-Type tyrosine kinase. AXL and its ligand, Gas6, in pediatric thyroid carcinomas around Chernobyl. Thyroid 12, 971-975 (2002).
23. G. Berclaz, H. J. Altermatt, V. Rohrbach, I. Kieffer, E. Dreher, A. C. Andres, Estrogen dependent expression of the receptor tyrosine kinase AXL in normal and malignant human breast. Ann. Oncol. 12, 819-824 (2001).
24. Y. S. Shieh, C. Y. Lai, Y. R. Kao, S. G. Shiah, Y. W. Chu, H. S. Lee, C. W. Wu, Expression of Axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia 7, 1058-1064 (2005).
25. M. Hutterer, P. Knyazev, A. Abate, M. Reschke, H. Maier, N. Stefanova, T. Knyazeva, V. Barbieri, M. Reindl, A. Muigg, H. Kostron, G. Stockhammer, A. Ullrich, Axl and growth arrest-Specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clin. Cancer Res. 14, 130-138 (2008).
26. J. Green, M. Ikram, J. Vyas, N. Patel, C. M. Proby, L. Ghali, I. M. Leigh, E. A. O?Toole, A. Storey, Overexpression of the Axl tyrosine kinase receptor in cutaneous SCCderived cell lines and tumours. Br. J. Cancer 94, 1446-1451 (2006).
27. J. B. M. Koorstra, C. A. Karikari, G. Feldmann, S. Bisht, P. L. Rojas, G. J. A. Offerhaus, H. Alvarez, A. Maitra, The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer Biol. Ther. 8, 618-626 (2009).
28. C. Gjerdrum, C. Tiron, T. Høiby, I. Stefansson, H. Haugen, T. Sandal, K. Collett, S. Li, E. McCormack, B. Gjertsen, D. R. Micklem, L. A. Akslen, C. Glackin, J. B. Lorens, Axl is an essential epithelial-To-Mesenchymal transition-Induced regulator of breast cancer metastasis and patient survival. Proc. Natl. Acad. Sci. U.S.A. 107, 1124-1129 (2010).
29. C. M. Johannessen, J. S. Boehm, S. Y. Kim, S. R. Thomas, L. Wardwell, L. A. Johnson, C. M. Emery, N. Stransky, A. P. Cogdill, J. Barretina, G. Caponigro, H. Hieronymus, R. R. Murray, K. Salehi-Ashtiani, D. E. Hill, M. Vidal, J. J. Zhao, X. Yang, O. Alkan, S. Kim, J. L. Harris, C. J. Wilson, V. E. Myer, P. M. Finan, D. E. Root, T. M. Roberts, T. Golub, K. T. Flaherty, R. Dummer, B. L.Weber,W. R. Sellers, R. Schlegel, J. A. Wargo,W. C. Hahn, L. A. Garraway, COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972 (2010).
30. L. Liu, J. Greger, H. Shi, Y. Liu, J. Greshock, R. Annan,W. Halsey, G. M. Sathe, A. M. Martin, T. M. Gilmer, Novel mechanism of lapatinib resistance in HER2-Positive breast tumor cells: Activation of AXL. Cancer Res. 69, 6871-6878 (2009).
31. Y. Shiozawa, E. A. Pedersen, L. R. Patel, A. M. Ziegler, A. M. Havens, Y. Jung, J. Wang, S. Zalucha, R. D. Loberg, K. J. Pienta, R. S. Taichman, Gas6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia 12, 116-127 (2010).
32. K. Vuoriluoto, H. Haugen, S. Kiviluoto, J. P. Mpindi, J. Nevo, C. Gjerdrum, C. Tiron, J. B. Lorens, J. Ivaska, Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene 30, 1436-1448 (2011).
33. Z. Zhang, J. C. Lee, L. Lin, V. Olivas, V. Au, T. LaFramboise, M. Abdel-Rahman, X. Wang, A. D. Levine, J. K. Rho, Y. J. Choi, C.-M. Choi, S.-W. Kim, S. J. Jang, Y. S. Park,W. S. Kim, D. H. Lee, J.-S. Lee, V. A. Miller, M. Arcila, M. Ladanyi, P. Moonsamy, C. Sawyers, T. J. Boggon, P. C. Ma, C. Costa, M. Taron, R. Rosell, B. Halmos, T. G.Bivona, Activation of the AXL kinase causes resistance to EGFR-Targeted therapy in lung cancer. Nat. Genet. 44, 852-860 (2012).
34. K. Y. Tai, Y. S. Shieh, C. S. Lee, S. G. Shiah, C. W. Wu, Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-kB and Brg-1. Oncogene 27, 4044-4055 (2008).
35. P. McCloskey, J. Pierce, R. A. Koski, B. Varnum, E. T. Liu, Activation of the Axl receptor tyrosine kinase induces mitogenesis and transformation in 32D cells. Cell Growth Differ. 5, 1105-1117 (1994).
36. S. Hafizi, F. Alindri, R. Karlsson, B. Dahlbäck, Interaction of Axl receptor tyrosine kinase with C1-TEN, a novel C1 domain-Containing protein with homology to tensin. Biochem. Biophys. Res. Commun. 299, 793-800 (2002).
37. P. H. Huang, A. Mukasa, R. Bonavia, R. A. Flynn, Z. E. Brewer, W. K. Cavenee, F. B. Furnari, F. M. White, Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc. Natl. Acad. Sci. U.S.A. 104, 12867-12872 (2007).
38. J. Barretina, G. Caponigro, N. Stransky, K. Venkatesan, A. A. Margolin, S. Kim, C. J. Wilson, J. Lehár, G. V. Kryukov, D. Sonkin, A. Reddy, M. Liu, L. Murray,M. F. Berger, J. E. Monahan, P. Morais, J. Meltzer, A. Korejwa, J. Jané-Valbuena, F. A. Mapa, J. Thibault, E. Bric-Furlong, P. Raman, A. Shipway, I. H. Engels, J. Cheng, G. K. Yu, J. Yu, P. Aspesi, M. De Silva, K. Jagtap, M. D. Jones, L. Wang, C. Hatton, E. Palescandolo, S. Gupta, S. Mahan, C. Sougnez, R. C. Onofrio, T. Liefeld, L. MacConaill, W. Winckler, M. Reich, N. Li, J. P. Mesirov, S. B. Gabriel, G. Getz, K. Ardlie, V. Chan, V. E. Myer, B. L. Weber, J. Porter, M. Warmuth, P. Finan, J. L. Harris, M. Meyerson, T. R. Golub, M. P. Morrissey, W. R. Sellers, R. Schlegel, L. A. Garraway, The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
39. C. M. Bishop, Pattern Recognition and Machine Learning (Springer, New York, (2006).
40. Cancer Genome Atlas Network, Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
41. G. Zhuang, D. M. Brantley-Sieders, D. Vaught, J. Yu, L. Xie, S. Wells, D. Jackson, R. Muraoka-Cook, C. Arteaga, J. Chen, Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res. 70, 299-308 (2010).
42. M. J. Lee, A. S. Ye, A. K. Gardino, A. M. Heijink, P. K. Sorger, G. MacBeath, M. B. Yaffe, Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 149, 780-794 (2012).
43. M. Nagane, A. Levitzki, A. Gazit, W. K. Cavenee, H. J. Huang, Drug resistance of human glioblastoma cells conferred by a tumor-Specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-Like proteases. Proc. Natl. Acad. Sci. U.S.A. 95, 5724-5729 (1998).
44. Y. Li, X. Ye, C. Tan, J. A. Hongo, J. Zha, J. Liu, D. Kallop, M. J. C. Ludlam, L. Pei, Axl as a potential therapeutic target in cancer: Role of Axl in tumor growth, metastasis and angiogenesis. Oncogene 28, 3442-3455 (2009).
45. M. R. Mark, J. Chen, R. G. Hammonds, M. Sadick, P. J. Godowsk, Characterization of Gas6, a member of the superfamily of G domain-Containing proteins, as a ligand for Rse and Axl. J. Biol. Chem. 271, 9785-9789 (1996).
46. I. Hasanbasic, I. Rajotte, M. Blostein, The role of g-Carboxylation in the anti-Apoptotic function of gas6. J. Thromb. Haemost. 3, 2790-2797 (2005).
47. A. S. Meyer, S. K. Hughes-Alford, J. E. Kay, A. Castillo, A. Wells, F. B. Gertler, D. A. Lauffenburger, 2D protrusion but not motility predicts growth factor-Induced cancer cell migration in 3D collagen. J. Cell Biol. 197, 721-729 (2012).
48. S. Gusenbauer, P. Vlaicu, A. Ullrich, HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors. Oncogene 10.1038/onc.2012.396 (2012).
49. E. T. Roussos, M. Balsamo, S. K. Alford, J. B. Wyckoff, B. Gligorijevic, Y. Wang, M. Pozzuto, R. Stobezki, S. Goswami, J. E. Segall, D. A. Lauffenburger, A. R. Bresnick, F. B. Gertler, J. S. Condeelis, Mena invasive (MenaINV) promotes multicellular streaming motility and transendothelial migration in a mouse model of breast cancer. J. Cell Sci. 124, 2120-2131 (2011).
50. L. Cerchia, C. L. Esposito, S. Camorani, A. Rienzo, L. Stasio, L. Insabato, A. Affuso, V. De Franciscis, Targeting Axl with an high-Affinity inhibitory aptamer. Mol. Ther. 20, 2291-2303 (2012).
51. X. Ye, Y. Li, S. Stawicki, S. Couto, J. Eastham-Anderson, D. Kallop, R. Weimer, Y. Wu, L. Pei, An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 29, 5254-5264 (2010).
52. T. Martens, N. O. Schmidt, C. Eckerich, R. Fillbrandt, M. Merchant, R. Schwall, M.Westphal, K. Lamszus, A novel one-Armed anti-C-Met antibody inhibits glioblastoma growth in vivo. Clin. Cancer Res. 12, 6144-6152 (2006).
53. H. Jin, R. Yang, Z. Zheng, M. Romero, J. Ross, H. Bou-Reslan, R. A. D. Carano, I. Kasman, E. Mai, J. Young, J. Zha, Z. Zhang, S. Ross, R. Schwall, G. Colbern, M. Merchant, MetMAb, the one-Armed 5D5 anti-C-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res. 68, 4360-4368 (2008).
54. S. Holland, A. Pan, C. Franci, Y. Hu, B. Chang, W. Li, M. Duan, A. Torneros, J. Yu, T. J. Heckrodt, J. Zhang, P. Ding, A. Apatira, J. Chua, R. Brandt, P. Pine, D. Goff, R. Singh, D. G. Payan, Y. Hitoshi, R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res. 4, 1544-1554 (2010).
55. G. J. Riely, M. G. Kris, B. Zhao, T. Akhurst, D. T. Milton, E. Moore, L. Tyson, W. Pao, N. A. Rizvi, L. H. Schwartz, V. A. Miller, Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin. Cancer Res. 13, 5150-5155 (2007).
56. J. E. Chaft, G. R. Oxnard, C. S. Sima, M. G. Kris, V. A. Miller, G. J. Riely, Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-Mutant lung cancer and acquired resistance to erlotinib or gefitinib: Implications for clinical trial design. Clin. Cancer Res. 17, 6298-6303 (2011).
57. O. Pop, A. Pirvu, A. C. Toffart, D. Moro-Sibilot, Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib. J. Thorac. Oncol. 7, e1-E2 (2012).
58. C. Y. Yeh, S. M. Shin, H. H. Yeh, T. J. Wu, J. W. Shin, T. Y. Chang, G. Raghavaraju, C. T. Lee, J. H. Chiang, V. S. Tseng, Y. C. G. Lee, C. H. Shen, N. H. Chow, H. S. Liu, Transcriptional activation of the Axl and PDGFR-A by c-Met through a ras-And Srcindependent mechanism in human bladder cancer. BMC Cancer 11, 139 (2011).
59. W. R. Greco, G. Bravo, J. C. Parsons, The search for synergy: A critical review from a response surface perspective. Pharmacol. Rev. 47, 331-385 (1995).
60. B. Efron, G. Gong, A leisurely look at the bootstrap, the jackknife, and cross-validation. Am. Stat. 37, 36-48 (1983).
61. C. M. Hurvich, C. L. Tsai, Bias of the corrected AIC criterion for underfitted regression and time series models. Biometrika 78, 499-509 (1991).
62. R. Milo, P. Jorgensen, U. Moran, G. Weber, M. Springer, BioNumbers-The database of key numbers in molecular and cell biology. Nucleic Acids Res. 38, D750-D753 (2010).